VIVA BIOTECH HOLDINGS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.44 HKD | +3.53% |
|
-2.22% | -58.10% |
| Mar. 28 | Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 18 | Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company's core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -58.10% | 116M | |
| +25.46% | 659B | |
| +25.41% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.68% | 215B | |
| +7.86% | 210B | |
| -6.75% | 200B | |
| -8.79% | 149B |
- Stock Market
- Equities
- 1873 Stock
- News Viva Biotech Holdings
- Viva Biotech : Raises $280 Million from Convertible Bond Sale; Files for Bourse Listing
